Trandolapril With Verapamil Hydrochloride-Sr

Not recommended CardiovascularRestrictedLater-line line

Hypertension in a patient who is stabilised on treatment with trandolapril 4 mg and verapamil hydrochloride sustained release 240 mg.

Submissions

1 resub

2006–06

On the record

—

ICER range

Cost-min

Cost basis

Decision on record

1 decision

Meeting Nov 2007 Not recommended Anti-hypertensive no PSD

Access path

1 submission · public record

Nov 2006
Recommended · restricted
vs trandolapril 4 mg and verapamil hydrochloride sustained…
PBS listing · Restricted

RecommendedDeferredNot recommended

Cost-effectiveness

Cost-minimisation analysis performed; no ICER calculated

Decision context

Populationpatients who are stabilised on treatment with trandolapril 4 mg and verapamil hydrochloride sustained release 240 mg

Submission history

1 entries

Decided	Outcome	Comparator	ICER	Evidence
Nov 2006	Recommended · restricted	trandolapril 4 mg and verapamil hydrochloride sustained release 240 mg given as monotherapy	—	RCT · DBP

Clinical evidence

Trials cited in the PSDs · ClinicalTrials.gov

Trial	Phase	N	Primary outcome	Status
STAR	Ph 4	280	Oral Glucose Tolerance	completed

Similar precedents

By decision profile

Trandolapril With Verapamil78%Ramipril With Felodipine69%Lercanidipine With Enalapril69%Valsartan With Hydrochlorothiazide68%Telmisartan With Amlodipine67%Olmesartan Medoxomil With Amlodipine67%Amlodipine Besylate With Valsartan65%Losartan64%

Regulatory · TGA

Label narrower than PBS population — PBAC restricts to patients already stabilised on specific component doses; TGA label permits initiation in all hypertension patients.